EUVIMEDPoznaj EUVIMED
Multizentrische StudieÜbersichtsarbeitOpen access · CC BY-NC 4.0

Genotype‐directed therapy for non–small cell lung cancer diagnosed during pregnancy: A pooled analysis of seven cases from the Cancer and Pregnancy Registry with maternal and neonatal outcomes and review of the literature

Reed Firestone iD, John Gaughan, Elyce Cardonick

Acta Obstetricia et Gynecologica Scandinavica · 2026

DOI: 10.1111/aogs.70303 ↗

At a glance

Multizentrische Studie in Acta Obstetricia et Gynecologica Scandinavica, 2026. Written by Reed Firestone and 2 co-authors. Institution: Department of Medicine, Thomas Jefferson University Hospital, Philadelphia, Pennsylvania, USA. Major MEDLINE topics: Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Pregnancy Complications, Neoplastic. 31 references. The full text is freely available (open access, CC BY-NC 4.0).

AbstraktSubjectsDane bibliograficzneCiteRelated studies

Abstract (original language)

Introduction

Pregnant patients with cancer are routinely excluded from the clinical trials, limiting the evidence to guide the management of advanced malignancies during pregnancy. Data regarding maternal and neonatal outcomes associated with genotype‐directed therapy for non‐small cell lung cancer (NSCLC) during pregnancy remain limited. Material and Methods We conducted a retrospective multicenter, pooled analysis of pregnant patients diagnosed with NSCLC between 2002 and 2024 who were enrolled in the Cancer and Pregnancy Registry ( ClinicalTrials.gov identifier: NCT02749474). Consecutive cases diagnosed during pregnancy were included. Clinical presentation, tumor histology and stage, biomarker and molecular profiling, oncologic treatment administered during pregnancy, obstetric management, maternal outcomes, and neonatal outcomes including pediatric developmental follow‐up were systematically reviewed and analyzed.

Results

Seven pregnant patients were diagnosed with NSCLC at a median gestational age of 22.4 weeks (range, 10.4–28.8 weeks). Five patients presented with stage IV disease, one with stage III disease, and one with stage II disease. Biomarker testing identified actionable alterations in all 6 patients who underwent testing, including epidermal growth factor receptor (EGFR) mutations or amplification ( n = 4), anaplastic lymphoma kinase (ALK) rearrangement ( n = 1), and ROS1 rearrangement ( n = 1). Biomarker‐directed therapy, including osimertinib or alectinib, was administered during the second or third trimester in 3 patients. All pregnancies resulted in live births, including one dichorionic diamniotic twin gestation, yielding eight infants. Median gestational age at delivery was 34.9 weeks. Five infants were small for gestational age, and two required early intervention for prematurity‐related developmental delays. No congenital anomalies or placental metastases were observed. Four patients remained alive and clinically stable at least 2.3 years after diagnosis, while all mothers survived to or beyond their child's first birthday.

Conclusions

In this limited retrospective study, biomarker‐directed therapy during pregnancy was associated with maternal disease control and continuation of pregnancy into later gestation in selected patients. No major fetal toxicity signal was identified; however, these findings should not be interpreted as establishing the safety of targeted therapy during pregnancy. Early biomarker testing and individualized multidisciplinary management may help inform treatment decision‐making for carefully selected patients with NSCLC diagnosed during pregnancy.

Subjects

MeSH terms (MEDLINE)

Carcinoma, Non-Small-Cell LungLung NeoplasmsPregnancy Complications, NeoplasticHumansFemalePregnancyRetrospective StudiesAdultPregnancy OutcomeRegistriesInfant, NewbornAntineoplastic AgentsGenotype

Author keywords

NSCLCgestational cancerlung cancertargeted therapytumor biomarkers

Substances

Antineoplastic Agents

Authors and institutions

  • Department of Medicine, Thomas Jefferson University Hospital, Philadelphia, Pennsylvania, USA.
  • Department of Biostatistics/Research, Cooper Medical School at Rowan University, Camden, New Jersey, USA.
  • Department of Obstetrics and Gynecology, Cooper University Hospital, Camden, New Jersey, USA.

ORCID profiles: Reed Firestone

Cite

APA

Firestone, R., Gaughan, J., & Cardonick, E. (2026). Genotype‐directed therapy for non–small cell lung cancer diagnosed during pregnancy: A pooled analysis of seven cases from the Cancer and Pregnancy Registry with maternal and neonatal outcomes and review of the literature. Acta Obstetricia et Gynecologica Scandinavica. https://doi.org/10.1111/aogs.70303

Vancouver

Firestone R, Gaughan J, Cardonick E. Genotype‐directed therapy for non–small cell lung cancer diagnosed during pregnancy: A pooled analysis of seven cases from the Cancer and Pregnancy Registry with maternal and neonatal outcomes and review of the literature. Acta Obstetricia et Gynecologica Scandinavica. 2026. doi:10.1111/aogs.70303

BibTeX
@article{Firestone2026,
  author = {Firestone, Reed and Gaughan, John and Cardonick, Elyce},
  title = {Genotype‐directed therapy for non–small cell lung cancer diagnosed during pregnancy: A pooled analysis of seven cases from the Cancer and Pregnancy Registry with maternal and neonatal outcomes and review of the literature},
  journal = {Acta Obstetricia et Gynecologica Scandinavica},
  year = {2026},
  doi = {10.1111/aogs.70303}
}
Start for free →